PL3220891T3 - Preparat podjęzykowy riluzolu - Google Patents
Preparat podjęzykowy riluzoluInfo
- Publication number
- PL3220891T3 PL3220891T3 PL15823415T PL15823415T PL3220891T3 PL 3220891 T3 PL3220891 T3 PL 3220891T3 PL 15823415 T PL15823415 T PL 15823415T PL 15823415 T PL15823415 T PL 15823415T PL 3220891 T3 PL3220891 T3 PL 3220891T3
- Authority
- PL
- Poland
- Prior art keywords
- riluzole
- sublingual formulation
- sublingual
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083094P | 2014-11-21 | 2014-11-21 | |
| PCT/US2015/061114 WO2016081472A1 (en) | 2014-11-21 | 2015-11-17 | Sublingual formulation of riluzole |
| EP15823415.3A EP3220891B1 (en) | 2014-11-21 | 2015-11-17 | Sublingual formulation of riluzole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3220891T3 true PL3220891T3 (pl) | 2020-08-24 |
Family
ID=55085882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15823415T PL3220891T3 (pl) | 2014-11-21 | 2015-11-17 | Preparat podjęzykowy riluzolu |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11660267B2 (pl) |
| EP (3) | EP3616686B8 (pl) |
| JP (3) | JP6753860B2 (pl) |
| KR (2) | KR102580378B1 (pl) |
| CN (1) | CN107249567B (pl) |
| AU (2) | AU2015350148B2 (pl) |
| BR (1) | BR112017010423B1 (pl) |
| CA (1) | CA2967662A1 (pl) |
| CY (1) | CY1122469T1 (pl) |
| DK (1) | DK3220891T3 (pl) |
| EA (1) | EA038518B1 (pl) |
| ES (2) | ES2751300T3 (pl) |
| HR (1) | HRP20191892T8 (pl) |
| HU (1) | HUE046869T2 (pl) |
| IL (2) | IL252285B (pl) |
| LT (1) | LT3220891T (pl) |
| MX (1) | MX368838B (pl) |
| PH (1) | PH12017500934A1 (pl) |
| PL (1) | PL3220891T3 (pl) |
| PT (1) | PT3220891T (pl) |
| RS (1) | RS59490B1 (pl) |
| SG (1) | SG11201703896QA (pl) |
| SI (1) | SI3220891T1 (pl) |
| WO (1) | WO2016081472A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10584101B2 (en) | 2016-10-11 | 2020-03-10 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| MX2020008680A (es) * | 2018-02-21 | 2020-09-25 | Ai Therapeutics Inc | Terapia de combinacion con apilimod y agentes glutamatergicos. |
| KR20210024475A (ko) * | 2018-05-27 | 2021-03-05 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 질환 치료를 위한 릴루졸 경구 붕해 정제의 용도 |
| EA202190544A1 (ru) * | 2018-08-16 | 2021-06-18 | Биохэйвен Терапьютикс Лтд. | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний |
| IL292359A (en) * | 2019-10-22 | 2022-06-01 | Arvinas Operations Inc | Prostate cancer treatment methods |
| CA3193824A1 (en) * | 2020-10-05 | 2022-04-14 | Ana PEREIRA | Riluzole for the treatment of alzheimer's disease |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN113876735B (zh) * | 2021-10-20 | 2023-05-12 | 陇南市第一人民医院 | 一种利鲁唑微球制剂及其制备方法 |
| KR102625977B1 (ko) | 2021-11-24 | 2024-01-17 | 부산대학교 산학협력단 | 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492258A1 (fr) | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| FR2702148B1 (fr) * | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
| WO1995001782A2 (en) | 1993-07-09 | 1995-01-19 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| DE59711346D1 (de) * | 1996-12-20 | 2004-04-01 | Nutrinova Gmbh | Verfahren zur verstärkung der süsskraft und zur geschmacksverbesserung einer mischung hochintensiver süssstoffe |
| ATE421318T1 (de) | 1997-02-20 | 2009-02-15 | Massachusetts Inst Technology | Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben |
| ES2263216T3 (es) | 1997-07-25 | 2006-12-01 | Alpex Pharma S.A. | Procedimiento para la preparacion de un granulado adecuado para la preparacion de comprimidos solubles en la boca rapidamente disgregables. |
| EP1133281A1 (en) | 1998-11-20 | 2001-09-19 | RTP Pharma Inc. | Dispersible phospholipid stabilized microparticles |
| EP1135105B1 (en) * | 1998-12-09 | 2005-03-02 | Chiron Corporation | Use of a neurologic agent for the manufacture of a medicament for the treatment of a central nervous system disorder |
| FR2787028B1 (fr) * | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| JP2001328947A (ja) * | 2000-05-19 | 2001-11-27 | Ritsuko Senba | 脳由来神経栄養因子発現促進剤 |
| US6432992B1 (en) * | 2000-06-05 | 2002-08-13 | Aventis Pharm Sa | Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| US6908626B2 (en) | 2001-10-12 | 2005-06-21 | Elan Pharma International Ltd. | Compositions having a combination of immediate release and controlled release characteristics |
| US7993674B2 (en) | 2002-02-13 | 2011-08-09 | Weibel Michael K | Drug dose-form and method of manufacture |
| IL163666A0 (en) * | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
| WO2004105756A2 (en) * | 2003-05-29 | 2004-12-09 | Novartis Ag | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| EP1778286A4 (en) * | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US8048449B2 (en) | 2005-12-27 | 2011-11-01 | Jubilant Organosys Ltd. | Mouth dissolving pharmaceutical composition and process for preparing the same |
| GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| EP1980240A1 (en) | 2007-04-11 | 2008-10-15 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
| JP5269894B2 (ja) | 2007-06-27 | 2013-08-21 | ハンミ ファーム． シーオー．， エルティーディー． | 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置 |
| US20110183942A1 (en) * | 2008-07-15 | 2011-07-28 | University Of Medicine And Dentistry Of New Jersey | Methods and Compositions for Treating Alzheimer's Disease |
| US8849441B2 (en) | 2008-10-31 | 2014-09-30 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| US8221480B2 (en) | 2008-10-31 | 2012-07-17 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| WO2010096869A1 (en) * | 2009-02-26 | 2010-09-02 | Steven Michael Weiss | An agent for improving inotropy and lusitropy, and for treating diseases causing or caused by poor contractility or relaxation of the heart |
| EP2228054A1 (en) * | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| US9241933B2 (en) * | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| RS53227B (en) * | 2011-03-01 | 2014-08-29 | Pharnext | THERAPY OF NEUROLOGICAL DISORDERS BY COMBINATION OF Baclofen AND ACAMPROSAT |
| UA113165C2 (xx) * | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| KR101951220B1 (ko) * | 2011-07-13 | 2019-02-22 | 싸이토키네틱스, 인코포레이티드 | 조합 als 치료법 |
| CA2864008C (en) * | 2012-03-01 | 2020-04-21 | Pharnext | New compositions for treating amyotrophic lateral sclerosis |
| BR112017010440A2 (pt) | 2014-11-21 | 2017-12-26 | Biohaven Pharm Holding Co Ltd | administração sublingual de riluzol |
| SG11201706831RA (en) * | 2015-03-03 | 2017-09-28 | Biohaven Pharm Holding Co Ltd | Riluzole prodrugs and their use |
-
2015
- 2015-11-17 AU AU2015350148A patent/AU2015350148B2/en active Active
- 2015-11-17 KR KR1020177016906A patent/KR102580378B1/ko active IP Right Grant
- 2015-11-17 PT PT158234153T patent/PT3220891T/pt unknown
- 2015-11-17 ES ES15823415T patent/ES2751300T3/es active Active
- 2015-11-17 CN CN201580073630.4A patent/CN107249567B/zh active Active
- 2015-11-17 CA CA2967662A patent/CA2967662A1/en active Pending
- 2015-11-17 SI SI201530956T patent/SI3220891T1/sl unknown
- 2015-11-17 MX MX2017006446A patent/MX368838B/es active IP Right Grant
- 2015-11-17 US US15/100,160 patent/US11660267B2/en active Active
- 2015-11-17 EA EA201790958A patent/EA038518B1/ru unknown
- 2015-11-17 EP EP19186196.2A patent/EP3616686B8/en active Active
- 2015-11-17 KR KR1020237031525A patent/KR20230135183A/ko not_active Application Discontinuation
- 2015-11-17 EP EP21169884.0A patent/EP4039247A3/en active Pending
- 2015-11-17 WO PCT/US2015/061114 patent/WO2016081472A1/en active Application Filing
- 2015-11-17 BR BR112017010423-7A patent/BR112017010423B1/pt active IP Right Grant
- 2015-11-17 DK DK15823415T patent/DK3220891T3/da active
- 2015-11-17 PL PL15823415T patent/PL3220891T3/pl unknown
- 2015-11-17 RS RS20191376A patent/RS59490B1/sr unknown
- 2015-11-17 HU HUE15823415A patent/HUE046869T2/hu unknown
- 2015-11-17 ES ES19186196T patent/ES2882783T3/es active Active
- 2015-11-17 EP EP15823415.3A patent/EP3220891B1/en active Active
- 2015-11-17 JP JP2017545858A patent/JP6753860B2/ja active Active
- 2015-11-17 SG SG11201703896QA patent/SG11201703896QA/en unknown
- 2015-11-17 LT LT15823415T patent/LT3220891T/lt unknown
-
2017
- 2017-05-15 IL IL252285A patent/IL252285B/en active IP Right Grant
- 2017-05-19 PH PH12017500934A patent/PH12017500934A1/en unknown
-
2019
- 2019-10-18 HR HRP20191892TT patent/HRP20191892T8/hr unknown
- 2019-10-22 CY CY20191101095T patent/CY1122469T1/el unknown
-
2020
- 2020-08-20 JP JP2020139429A patent/JP2021001173A/ja active Pending
- 2020-10-20 IL IL278188A patent/IL278188A/en unknown
- 2020-10-25 US US17/079,498 patent/US20210038499A1/en active Pending
-
2021
- 2021-02-17 AU AU2021201034A patent/AU2021201034B2/en active Active
-
2023
- 2023-02-03 JP JP2023015640A patent/JP2023065398A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250089A0 (en) | Metrology of multiple sampling processes | |
| IL278188A (en) | Sublingual formulation of riluzole | |
| SG11201609265RA (en) | Characterizing states of subject | |
| IL252283A0 (en) | Sublingual administration of riluzole | |
| PT3102555T (pt) | Composições de compostos e seus usos | |
| SI3154526T1 (sl) | Trdne oblike sofosbuvira | |
| ZA201700022B (en) | A novel formulation of meloxicam | |
| IL246979A0 (en) | Crystalline forms of sofosbuvir | |
| IL249130A0 (en) | Preparation of piperidine-4-carbthioamide | |
| GB2544217B (en) | Chlorination of sucrose-6-esters | |
| GB201407822D0 (en) | Use of a composition | |
| IL249332A0 (en) | Crystalline forms of sofosbuvir | |
| GB201412359D0 (en) | Composition of objects | |
| GB201412089D0 (en) | Composition of objects | |
| GB201418410D0 (en) | use of compositions of matter | |
| GB201418230D0 (en) | Construction of surfaces | |
| GB201417347D0 (en) | Prodrugs of delanzomib | |
| GB201417348D0 (en) | Prodrugs of lxazomib | |
| HUP1400294A2 (hu) | Clopidogrel új alkalmazása | |
| TWM489614U (en) | Structure of bathroom accessory | |
| GB201405157D0 (en) | Theory of international law | |
| GB201405142D0 (en) | Theory of restoration | |
| GB201404705D0 (en) | Theory of Conceptual art | |
| GB201414267D0 (en) | Chlorination of sucrose-6-esters | |
| GB201405158D0 (en) | Theory of european law |